Epoetin alfa use in gynecology: Past, present and future

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 46, Issue 5 SUPPL., 2001, Pages 539-544

  Bachmann, Gloria A ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Anemia; Epoetin alfa; Fatigue; Gynecologic surgical procedures; Quality of life

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CANCER PATIENT; CLINICAL RESEARCH; FATIGUE; GYNECOLOGY; HEMATOCRIT; HUMAN; IRON THERAPY; MALIGNANT NEOPLASTIC DISEASE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SURGICAL PATIENT;

ANEMIA; EPOETIN ALFA; FATIGUE; FEMALE; FORECASTING; GYNECOLOGIC SURGICAL PROCEDURES; HEMATINICS; HUMANS; PERIOPERATIVE CARE; QUALITY OF LIFE; SAFETY; SURGICAL PROCEDURES, ELECTIVE; TREATMENT OUTCOME;

EID: 0035015968     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Kanter MH, van Maanen D, Anders KH, et al: Preoperative autologous blood donations before elective hysterectomy. JAMA 1996;276:798-801
2. Carlson KJ, Miller BA, Fowler FJ Jr: The Maine Women's Health Study: II. Outcomes of nonsurgical management of leiomyomas, abnormal bleeding, and chronic pelvic pain. Obstet Gynecol 1994;83:566-572
3. A prospective, randomized, controlled study comparing the perioperative administration of Procrit® (epoetin alfa) with iron supplementation versus iron supplementation alone in patients undergoing hysterectomy for benign gynecologic disease: Protocol PR 98-31-025. Raritan, New Jersey, Ortho Biotech, 1999
4. A prospective, randomized, study comparing the perioperative administration of Procrit® (epoetin alfa) with iron supplementation versus iron supplementation alone in patients undergoing abdominal hysterectomy or myomectomy for benign gynecologic disease: Protocol PR 98-31-031. Raritan, New Jersey, Ortho Biotech, 1998
5. Kurz CH, Marth CH, Windbichler G, et al: Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: A prospective, randomized, double-blind placebo-controlled multicenter study. Gynecol Oncol 1997;65:461-466
6. The Assessment of Fatigue in Hysterectomy Patients. McLean, Virginia, Wirthlin Worldwide, 1999
7. Keating EM, Ranawat CS, Cats-Baril W: Assessment of post-operative vigor in patients undergoing elective total joint arthroplasty: A concise patient-and caregiver-based instrument. Orthopedics (suppl) 1999;22:S119-S128
8. Skillings JR, Sridhar FG, Wong C, et al: The frequency of red cell transfusion for anemia in patients receiving chemotherapy: A retrospective cohort study. Am J Clin Oncol 1993;16: 22-25
9. Blajchman MA, Bordin JO: Mechanisms of transfusion-associated immunosuppression. Curr Opin Hematol 1994;1: 457-461
10. PROCRIT® package insert. Raritan, New Jersey, Ortho Biotech, 1999
11. Leitgeb C, Pecherstorfer M, Fritz E, et al: Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer 1994;73:2535-2542
12. Schipper H, Clinch J, McMurray A, et al: Measuring the quality of life of cancer patients: The Functional Living Index-Cancer: Development and validation. J Clin Oncol 1984;2:472-483
13. Canadian Orthopedic Perioperative Erythropoietin Study Group: Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. Lancet 1993;341: 1227-1232
14. Faris PM, Ritter MA, Abels RI: The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation: The American Erythropoietin Study Group. J Bone Joint Surg Am 1996;78:62-72
15. de Andrade JR, Jove M, Landon G, et al: Baseline hemoglobin as a predictor of risk of transfusion and response to Epoetin alfa in orthopedic surgery patients. Am J Orthop 1996; 25:533-542
16. Goldberg MA, McCutchen JW, Jove M, et al: A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. Am J Orthop 1996;25:544-552
17. Lepine LA, Hillis SD, Marchbanks PA, et al: Hysterectomy surveillance - United States: 1980-1993. MMWR 1997;46(SS-4):1-15
18. Iverson RE Jr, Chelmow D, Strohbehn K, et al: Relative morbidity of abdominal hysterectomy and myomectomy for management of uterine leiomyomas. Obstet Gynecol 1996; 88:415-419
19. Wood C, Maher P, Hill D: Bleeding associated with vaginal hysterectomy. Aust NZ J Obstet Gynaecol 1997;37:457-461
20. Rock JA, Thompson JD: Te Linde's Operative Gynecology. Eighth edition. Philadelphia, Lippincott-Raven, 1997
21. Donato DM: Surgical management of stage IB-IIA cervical carcinoma. Semin Surg Oncol 1999;16:232-235
22. Rehm M, Orth V, Kreimeier U, et al: Changes in intravascular volume during acute normovolemic hemodilution and intraoperative retransfusion in patients with radical hysterectomy. Anesthesiology 2000;92:657-664
23. Furuhashi M, Miyabe Y, Katsumata Y, et al: Comparison of complications of vaginal hysterectomy in patients with leiomyomas and in patients with adenomyosis. Arch Gynecol Obstet 1998;262:69-73
24. Dalakas MC, Mock V, Hawkins MJ: Fatigue: Definitions, mechanisms, and paradigms for study. Semin Oncol 1998; 25:48-53
25. Castell LM, Yamamoto T, Phoenix J, et al: The role of tryptophan in fatigue in different conditions of stress. Adv Exp Med Biol 1999;467:697-704
26. Stowell CP, Chandler H, Jove M, et al: An open-label, randomized study to compare the safety and efficacy of perioperative epoetin alfa with preoperative autologous blood donation in total joint arthroplasty. Orthopedics (suppl) 1999;22:S105-S112
27. Cella D, Mo F, Peterman A: Anemia, fatigue and quality of life in people with cancer and HIV infection (abstr). Blood (suppl 1) 1996;88:146a
28. Glaspy J, Bukowski R, Steinberg D, et al: Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice: Procrit Study Group. J Clin Oncol 1997;15:1218-1234
29. Littlewood TJ, Bajetta E, Cella D: Efficacy and quality of life outcomes of epoetin alfa in a double-blind, placebo-controlled multicenter study of cancer patients receiving non-platinum containing chemotherapy (abstr). Proc Am Soc Clin Oncol 1999;18:574a
30. Demetri GD, Kris M, Wade J, et al: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-3425
31. Abels RI, Larholt KM, Krantz KD, et al: Recombinant human erythropoietin (r-HuEPO) for the treatment of the anemia of cancer. In Blood Cell Growth Factors: Their Present and Future Use in Hematology and Oncology. Edited by MJ Murphy. Dayton, AlphaMed Press, 1991, pp 121-141
32. Munin MC, Rudy TE, Glynn NW, et al: Early inpatient rehabilitation after elective hip and knee arthroplasty. JAMA 1998;279:847-852
33. Piper BF, Lindsay AM, Dodd MJ: Fatigue mechanisms in cancer patients: Developing nursing theory. Oncol Nurs Forum 1987;14:17-23
34. Cella D: The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol (suppl 2) 1997;34:13-19
35. Martoni A, Panetta A, Angelelli B, et al: A phase II study of carboplatin and cyclophosphamide in advanced ovarian carcinoma. J Chemother 1993;5:47-51
36. Shapiro JD, Rothenberg ML, Sarosy GA, et al: Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer. Cancer 1998;83:1980-1988
37. Oliverio G, Canuti D, Tononi A, et al: Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients. J Chemother 1999;11:301-305
38. Kavanagh JJ, Kudelka AP, de Leon CG, et al: Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 1996;2:837-842
39. Groopman JE, Itri LM: Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999;91: 1616-1634
40. Obermair A, Handisurya A, Raider A, et al: The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients: A prospective review. Cancer 1998;83:726-731